HOME - Companies - Products
 
 
04 March 2024

FDA Clears AIOMEGA’s AIO Breathe for Treatment of Obstructive Sleep Apnea


AIOMEGA, a Texas biomedical company, announced that AIO BREATHE, their medical device that treats Obstructive Sleep Apnea, has been cleared by the Food and Drug Administration.

AIO BREATHE is a “new mandibular repositioning device” designed by Tyler, Texas-based Board Certified Sleep Physician Dr. Raghavendra V. Ghuge, MD, MBA, DABSM, FAASM. Ghuge is the founder and CEO of AIOMEGA.

“I designed AIO BREATHE, supported by multiple patents, to overcome several shortcomings of conventional oral appliances used for the treatment of OSA,” said Dr. Ghuge.

AIO Breathe Summary

AIO Breathe acts by increasing the patient’s airway during sleep, improving the ability to exchange air, thereby reducing the tendency to snore and alleviating signs of obstructive sleep apnea.

AIO Breathe features right and left protrusive flanges that engage with corresponding right and left vertical flanges. This engagement repositions the jaw to reflect the dentist’s prescribed anterior mandibular advancement and is maintained while the mouth is open or closed.

Additionally, mandibular plateaus guide the mandible downward, thus opening the anterior airway. The plateaus and flanges allow vertical opening of the jaw and work together to maintain advancement in open and closed mouth positions.

Indications for Use

AIO Breathe is intended to reduce or alleviate snoring and mild to moderate Obstructive Sleep Apnea (OSA) while sleeping in adults.

The unique features of this Mandibular Repositioning Device along with lightweight and small form factor provide an attractive option for those who seek treatment of OSA.

OSA, a chronic medical sleep disorder affecting about 30% of the world’s population, is associated with lifelong oxygen deprivation and snoring during sleep. This may result in many cardiovascular and neurological complications such as Hypertension, Atrial Fibrillation, stroke, congestive heart failure and metabolic complications such as obesity and Diabetes. The conventional treatment of OSA is a CPAP device although a significant number of patients refuse or fail such therapy, and many are reluctant to seek help on account of hearing negative reports about CPAP. AIOMEGA’s AIO Breathe could provide a comfortable, convenient method of treatment to people around the world.


Source: www.sleeptyler.com

Related articles

AI dental company announces 510(k) clearance from the U.S. Food and Drug Administration for Overjet CBCT Assist.


Perimetrics, Inc., a dental technology company pioneering quantitative diagnostics, announced today that the U.S. Food and Drug Administration (FDA) has granted clearance for the InnerView...


DentalMonitoring, the leader in artificial intelligence (AI)-powered remote monitoring for orthodontics, has released a major software update introducing features and indications based on the...


Relu, a pioneer in artificial intelligence (AI)-assisted segmentation for dental labs and software companies, proudly announces the dual achievement of 510(k) clearance by the U.S. Food and Drug...


Orthobond Corporation, a leader in covalently-bound antibacterial surface technologies with broad applications in the medical device industry, announced that the U.S. Food and Drug Administration...


Read more

Dentistry Today recently attended a robotic-assisted dental implant procedure performed by Jay Neugarten, DDS, MD, FACS, utilizing the Yomi S robotic guidance s


State funding will create dedicated space for pediatric and adolescent care and improve access for people with disabilities across the lifespan


 
 
 
 

 
 
 
 

Most popular

 
 

Events